Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The company's website is www.rapporttherapeutics.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Rapport Therapeutics, Inc. does
In the company’s own words
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients with neurological and psychiatric disorders. The company's website is www.rapporttherapeutics.com.
Rapport was founded in February 2022 with support from Third Rock Ventures and Johnson & Johnson Innovation-JJDC to advance the discovery and development of receptor-associated protein (RAP) targeted precision neuromedicines. The company's scientific foundation stems from pioneering discoveries related to RAP function in the brain, which form the basis of its proprietary RAP technology platform. This platform enables a differentiated approach to generate precision small molecule product candidates by targeting neuronal receptor complexes with regional specificity in the brain.
The company's lead product candidate, RAP-219, is an AMPA receptor negative allosteric modulator designed to selectively target TARP8, a receptor-associated protein expressed primarily in the neocortex and mesial temporal lobe where focal onset seizures originate. RAP-219 has demonstrated positive results in Phase 2a proof-of-concept trials in adult patients with drug-resistant focal onset seizures and is being evaluated for additional indications including primary generalized tonic-clonic seizures and bipolar mania. The company is advancing RAP-219 toward Phase 3 clinical development and is also developing a long-acting injectable formulation to improve patient adherence.
Beyond RAP-219, Rapport has two advanced discovery-stage nicotinic acetylcholine receptor programs. The alpha-6-beta-4 nAChR program, represented by development candidate RAP-641, targets chronic pain and migraine through a non-opioid, non-CNS mechanism. The alpha-9-alpha-10 nAChR program focuses on potential therapies for hearing and vestibular disorders.
The company leverages its RAP technology platform through two distinct strategies: directly targeting RAPs as drug targets for neuroanatomical specificity, and using RAPs to unlock previously inaccessible receptors for drug discovery. Rapport maintains an exclusive global license agreement with Janssen Pharmaceutical NV for certain TARP8 and nAChR projects, providing access to foundational intellectual property and know-how that support its pipeline development.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 2012593
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Rapport Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Rapport Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Rapport Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Rapport Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Rapport Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”